Acute hepatic injury in four children with Dravet syndrome: Valproic acid, topiramate or acetaminophen?

نویسندگان

  • Joost Nicolai
  • Boudewijn Gunning
  • Piet L. Leroy
  • Berten Ceulemans
  • Johan S.H. Vles
چکیده

We describe four children with Dravet syndrome treated with the combination of valproic acid (VPA) and topiramate (TPM) who developed transient liver toxicity. The time-interval between fever, administration of acetaminophen, epileptic status and liver enzyme disturbances in our four cases suggests that accumulation of toxic acetaminophen-metabolites is possibly responsible for liver toxicity. If acetaminophen and its metabolites cause those liver problems in children treated with the combination of VPA and TPM, the advice to use acetaminophen for treating fever in children using this combination, should be changed. Only future clinical observations and research can solve this clinical dilemma.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Response to the comments on ‘Acute hepatic injury in a child with Dravet syndrome: No protective effect of stiripentol’

Goorhuis et al. add some very important information about the problem of medication-induced hepatotoxicity in children with Dravet syndrome. The girl they describe was treated with valproic acid, stiripentol and acetaminophen. Stiripentol is thought to prevent liver damage in acetaminophen intoxication. Stiripentol inhibits the synthesis of N-acetyl-pbenzoquinone-imine, a highly reactive acetam...

متن کامل

Acute hepatic injury in a child with Dravet syndrome: No protective effect of stiripentol

We read with interest the article by Nicolai et al. who described four children with Dravet syndrome treated with valproic acid (VPA) and topiramate (TPM), who all developed transient hepatic injury shortly after introduction of acetaminophen in therapeutic dosage. Based on the time interval between fever, administration of acetaminophen, epileptic status and liver enzyme disturbances, the auth...

متن کامل

Current therapeutic procedures in Dravet syndrome.

Dravet syndrome is a highly pharmaco-resistant form of epilepsy. Valproate and benzodiazepines are the first-line treatment but are usually insufficient therapeutic options. Lamotrigine, carbamazepine and high doses of intravenous phenobarbital can aggravate seizures and should be avoided. Topiramate, levetiracetam, bromide and ketogenic diet also provide substantial efficacy as adjunctive ther...

متن کامل

Dravet syndrome, what is new?

Dravet syndrome (DS) is one of the most severe genetic epilepsies of childhood. Charlotte Dravet described severe myoclonic epilepsy in infancy in 1978. Shortly after the initial report, many cases were published. Most of the cases have the SCN1A mutation. A variant of DS called borderline severe myoclonic epilepsy in infancy has similar clinical and electrographic features without myoclonus. T...

متن کامل

"Severe myoclonic epilepsy in infancy". Relevance for the clinician of severe epilepsy starting in infancy.

'Severe myoclonic epilepsy in infancy' or Dravet syndrome is a clear example of the impact of severe epilepsy on the developing child. Presenting with febrile seizures in infancy, children later on develop a severe epileptic syndrome with mental retardation. Nearly all children have life-threatening status epilepticus during the first two years of life. The clinical diagnosis can now be confirm...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Seizure

دوره 17  شماره 

صفحات  -

تاریخ انتشار 2008